SCHEMBL8738414

SCHEMBL8738414

COc1ccc(OC)c(Sc2ccc(C)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
ALDH1A1 P00352 6/20 0.58
HPGD P15428 2/20 0.58
GAA P10253 1/20 0.58
ALOX15 P16050 1/20 0.58
MAPK1 P28482 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
PTGIR P43119 1/20 0.52
TP53 P04637 1/20 0.48
LRRK2 Q5S007 4/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
ACHE P22303 2/20 0.47
HTR1A P08908 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31345518 1.00 MAPT (0.58) MAPTALDH1A1HPGDGAAALOX15
Nitrogen SCHEMBL10783880 0.97 MAPT (0.55) MAPTALDH1A1HPGDGAAALOX15
SCHEMBL31345533 0.86 MAPT (0.61) MAPTALDH1A1HPGDGAAALOX15
SCHEMBL8736422 0.84 ACHE (0.48) MAPTALDH1A1HPGDGAAALOX15
SCHEMBL2887157 0.84 PTGIR (0.50) MAPTALDH1A1MAPK1L3MBTL1PTGIR
SCHEMBL9487582 0.83 CA12 (0.60) MAPTALDH1A1MAPK1PTGIRLRRK2
SCHEMBL38663217 0.83 CA12 (0.60) MAPTALDH1A1MAPK1PTGIRLRRK2
SCHEMBL31345532 0.81 ALDH1A1 (0.56) MAPTALDH1A1HPGDGAAALOX15
SCHEMBL31345528 0.81 ALDH1A1 (0.56) MAPTALDH1A1HPGDGAAALOX15
SCHEMBL31345529 0.81 ALDH1A1 (0.56) MAPTALDH1A1HPGDGAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149706-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS DUMAS JACQUES (US) 2012-06-14 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120046290-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2012-02-23 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
EP-0561847-B1 PHOTOSENSITIVE POLYMERS AND PRINTING PLATES LASTRA SPA (IT) 1997-08-27 EP disclosed
EP-0561847-A1 PHOTOSENSITIVE POLYMERS AND PRINTING PLATES. LASTRA SPA (IT) 1993-09-29 EP disclosed
WO-1992010523-A1 PHOTOSENSITIVE POLYMERS AND PRINTING PLATES LASTRA S.P.A. (IT) 1992-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149706-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS MAPK1, MAP3K1, MAP3K7 MAPT 825/4885ALDH1A1 1451/4885HPGD 524/4885
US-20120046290-A1 INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS MAPK1, MAP3K1, MAP3K7 MAPT 825/4885ALDH1A1 1451/4885HPGD 524/4885
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF MAPT 3056/4885ALDH1A1 2759/4885HPGD 2117/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF MAPT 3056/4885ALDH1A1 2759/4885HPGD 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.